Newborn Screening for Medium Chain Acyl-CoA Dehydrogenase Deficiency in England: Prevalence, Predictive Value and Test Validity Based on 1.5 Million Screened Babies

Overview

Journal J Med Screen

Specialty Public Health

Date 2011 Dec 15

PMID 22166308

Citations 19

Authors

Juliet Oerton

Javaria M Khalid

Guy Besley

R Neil Dalton

Melanie Downing

Anne Green

Mick Henderson

Steve Krywawych

James Leonard

Brage S Andresen

Carol Dezateux

Affiliations

Soon will be listed here.

Abstract

Background: Medium chain acyl-CoA dehydrogenase deficiency (MCADD) is a rare, life-threatening condition. Early diagnosis by screening asymptomatic newborns may improve outcome, but the benefit to newborns identified with variants not encountered clinically is uncertain.

Objective: To estimate, overall and by ethnic group: screen-positive prevalence and predictive value (PPV); MCADD prevalence; proportion MCADD variants detected of predicted definite or uncertain clinical importance.

Setting: All births in areas of high ethnic minority prevalence in England.

Methods: Prospective multicentre pilot screening service; testing at age five to eight days; standardized screening, diagnostic and management protocols; independent expert review of screen-positive cases to assign MCADD diagnosis and predicted clinical importance (definite or uncertain).

Results: Approximately 1.5 million babies (79% white; 10% Asian) were screened. MCADD was confirmed in 147 of 190 babies with a positive screening result (screen-positive prevalence: 1.20 per 10,000; MCADD prevalence: 0.94 per 10,000; PPV 77% [95% CI 71-83]), comprising 103 (70%) with MCADD variants of definite clinical importance (95 white [95%]; 2 Asian [2%]) and 44 (30%) with variants of uncertain clinical importance (29 white [67%]; 12 Asian [28%]).

Conclusion: One baby in every 10,000 born in England is diagnosed with MCADD by newborn screening; around 60 babies each year. While the majority of MCADD variants detected are predicted to be of definite clinical importance, this varies according to ethnic group, with variants of uncertain importance most commonly found in Asian babies. These findings provide support for MCADD screening but highlight the need to take account of the ethnic diversity of the population tested at implementation.

Citing Articles

Epidemiology of inherited metabolic disorders in newborn screening: insights from three years of experience in Southern Iran.

Salarian L, Ilkhanipoor H, Amirhakimi A, Afshar Z, Nahid S, Ardekani F Orphanet J Rare Dis. 2025; 20(1):84.

PMID: 40001143 PMC: 11853994. DOI: 10.1186/s13023-025-03602-w.

Low ACADM expression predicts poor prognosis and suppressive tumor microenvironment in clear cell renal cell carcinoma.

Zhou L, Yin M, Guo F, Yu Z, Weng G, Long H Sci Rep. 2024; 14(1):9533.

PMID: 38664460 PMC: 11045743. DOI: 10.1038/s41598-024-59746-5.

Immunometabolic Profiling of Chronic Subdural Hematoma through Untargeted Mass Spectrometry Analysis: Preliminary Findings of a Novel Approach.

Kipele M, Buchfelder M, Taudte R, Stadlbauer A, Kinfe T, Bozhkov Y Diagnostics (Basel). 2023; 13(21).

PMID: 37958242 PMC: 10650661. DOI: 10.3390/diagnostics13213345.

Policy-making and implementation for newborn bloodspot screening in Europe: a comparison between EURORDIS principles and UK practice.

Lombardo S, Seedat F, Elliman D, Marshall J Lancet Reg Health Eur. 2023; 33:100714.

PMID: 37954001 PMC: 10636270. DOI: 10.1016/j.lanepe.2023.100714.

Medium-chain Acyl-COA dehydrogenase deficiency: Pathogenesis, diagnosis, and treatment.

Mason E, Hindmarch C, Dunham-Snary K Endocrinol Diabetes Metab. 2022; 6(1):e385.

PMID: 36300606 PMC: 9836253. DOI: 10.1002/edm2.385.

References

Andresen B, Dobrowolski S, OReilly L, Muenzer J, McCandless S, Frazier D . Medium-chain acyl-CoA dehydrogenase (MCAD) mutations identified by MS/MS-based prospective screening of newborns differ from those observed in patients with clinical symptoms: identification and characterization of a new, prevalent mutation that.... Am J Hum Genet. 2001; 68(6):1408-18. PMC: 1226127. DOI: 10.1086/320602. View

Zytkovicz T, Fitzgerald E, Marsden D, Larson C, Shih V, Johnson D . Tandem mass spectrometric analysis for amino, organic, and fatty acid disorders in newborn dried blood spots: a two-year summary from the New England Newborn Screening Program. Clin Chem. 2001; 47(11):1945-55. View

Seymour C, Thomason M, Chalmers R, Addison G, Bain M, Cockburn F . Newborn screening for inborn errors of metabolism: a systematic review. Health Technol Assess. 1997; 1(11):i-iv, 1-95. View

Touma E, Charpentier C . Medium chain acyl-CoA dehydrogenase deficiency. Arch Dis Child. 1992; 67(1):142-5. PMC: 1793557. DOI: 10.1136/adc.67.1.142. View

Wilson C, Champion M, Collins J, Clayton P, Leonard J . Outcome of medium chain acyl-CoA dehydrogenase deficiency after diagnosis. Arch Dis Child. 1999; 80(5):459-62. PMC: 1717923. DOI: 10.1136/adc.80.5.459. View

Derks T, Boer T, van Assen A, Bos T, Ruiter J, Waterham H . Neonatal screening for medium-chain acyl-CoA dehydrogenase (MCAD) deficiency in The Netherlands: the importance of enzyme analysis to ascertain true MCAD deficiency. J Inherit Metab Dis. 2008; 31(1):88-96. DOI: 10.1007/s10545-007-0492-3. View

Maier E, Liebl B, Roschinger W, Nennstiel-Ratzel U, Fingerhut R, Olgemoller B . Population spectrum of ACADM genotypes correlated to biochemical phenotypes in newborn screening for medium-chain acyl-CoA dehydrogenase deficiency. Hum Mutat. 2005; 25(5):443-52. DOI: 10.1002/humu.20163. View

Kennedy S, Potter B, Wilson K, Fisher L, Geraghty M, Milburn J . The first three years of screening for medium chain acyl-CoA dehydrogenase deficiency (MCADD) by newborn screening ontario. BMC Pediatr. 2010; 10:82. PMC: 2996355. DOI: 10.1186/1471-2431-10-82. View

Khalid J, Oerton J, Besley G, Dalton N, Downing M, Green A . Relationship of octanoylcarnitine concentrations to age at sampling in unaffected newborns screened for medium-chain acyl-CoA dehydrogenase deficiency. Clin Chem. 2010; 56(6):1015-21. DOI: 10.1373/clinchem.2010.143891. View

10.

Maier E, Pongratz J, Muntau A, Liebl B, Nennstiel-Ratzel U, Busch U . Dissection of biochemical borderline phenotypes in carriers and genetic variants of medium-chain acyl-CoA dehyrogenase deficiency: implications for newborn screening [corrected]. Clin Genet. 2009; 76(2):179-87. DOI: 10.1111/j.1399-0004.2009.01217.x. View

11.

Okun J, Kolker S, Schulze A, Kohlmuller D, Olgemoller K, Lindner M . A method for quantitative acylcarnitine profiling in human skin fibroblasts using unlabelled palmitic acid: diagnosis of fatty acid oxidation disorders and differentiation between biochemical phenotypes of MCAD deficiency. Biochim Biophys Acta. 2002; 1584(2-3):91-8. DOI: 10.1016/s1388-1981(02)00296-2. View

12.

Andresen B, Bross P, Udvari S, Kirk J, Gray G, Kmoch S . The molecular basis of medium-chain acyl-CoA dehydrogenase (MCAD) deficiency in compound heterozygous patients: is there correlation between genotype and phenotype?. Hum Mol Genet. 1997; 6(5):695-707. DOI: 10.1093/hmg/6.5.695. View

13.

MORRIS A, Taylor R, Lightowlers R, Aynsley-Green A, Bartlett K, Turnbull D . Medium chain acyl-CoA dehydrogenase deficiency caused by a deletion of exons 11 and 12. Hum Mol Genet. 1995; 4(4):747-9. DOI: 10.1093/hmg/4.4.747. View

14.

Gregersen N, Andresen B, Pedersen C, Olsen R, Corydon T, Bross P . Mitochondrial fatty acid oxidation defects--remaining challenges. J Inherit Metab Dis. 2008; 31(5):643-57. DOI: 10.1007/s10545-008-0990-y. View

15.

Nennstiel-Ratzel U, Arenz S, Maier E, Knerr I, Baumkotter J, Roschinger W . Reduced incidence of severe metabolic crisis or death in children with medium chain acyl-CoA dehydrogenase deficiency homozygous for c.985A>G identified by neonatal screening. Mol Genet Metab. 2005; 85(2):157-9. DOI: 10.1016/j.ymgme.2004.12.010. View

16.

Pourfarzam M, Morris A, Appleton M, Craft A, Bartlett K . Neonatal screening for medium-chain acyl-CoA dehydrogenase deficiency. Lancet. 2001; 358(9287):1063-4. DOI: 10.1016/S0140-6736(01)06199-2. View

17.

Lindner M, Hoffmann G, Matern D . Newborn screening for disorders of fatty-acid oxidation: experience and recommendations from an expert meeting. J Inherit Metab Dis. 2010; 33(5):521-6. DOI: 10.1007/s10545-010-9076-8. View

18.

Pollitt R, Leonard J . Prospective surveillance study of medium chain acyl-CoA dehydrogenase deficiency in the UK. Arch Dis Child. 1998; 79(2):116-9. PMC: 1717653. DOI: 10.1136/adc.79.2.116. View

19.

Hoffmann G, von Kries R, Klose D, Lindner M, Schulze A, Muntau A . Frequencies of inherited organic acidurias and disorders of mitochondrial fatty acid transport and oxidation in Germany. Eur J Pediatr. 2004; 163(2):76-80. DOI: 10.1007/s00431-003-1246-3. View

20.

Leonard J, Dezateux C . Newborn screening for medium chain acyl CoA dehydrogenase deficiency. Arch Dis Child. 2008; 94(3):235-8. DOI: 10.1136/adc.2007.134957. View